TY - JOUR
T1 - Pan-filovirus serum neutralizing antibodies in a subset of Congolese ebolavirus infection survivors
AU - Bramble, Matthew S.
AU - Hoff, Nicole
AU - Gilchuk, Pavlo
AU - Mukadi, Patrick
AU - Lu, Kai
AU - Doshi, Reena H.
AU - Steffen, Imke
AU - Nicholson, Bradly P.
AU - Lipson, Allen
AU - Vashist, Neerja
AU - Sinai, Cyrus
AU - Spencer, D'andre
AU - Olinger, Garrard
AU - Wemakoy, Emile Okitolonda
AU - Illunga, Benoit Kebela
AU - Pettitt, James
AU - Logue, James
AU - Marchand, Jonathan
AU - Varughese, Justin
AU - Bennett, Richard S.
AU - Jahrling, Peter
AU - Cavet, Guy
AU - Serafini, Tito
AU - Saphire, Erica Ollmann
AU - Vilain, Eric
AU - Muyembe-Tamfum, Jean Jacques
AU - Hensely, Lisa E.
AU - Simmons, Graham
AU - Crowe, James E.
AU - Rimoin, Anne W.
N1 - Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.This is an Open Access article distributed under the terms of the Creative Commons Attribution License
PY - 2018/11/5
Y1 - 2018/11/5
N2 - One year after a Zaire ebolavirus (EBOV) outbreak occurred in the Boende Health Zone of the Democratic Republic of the Congo during 2014, we sought to determine the breadth of immune response against diverse filoviruses including EBOV, Bundibugyo (BDBV), Sudan (SUDV), and Marburg (MARV) viruses. After assessing the 15 survivors, 5 individuals demonstrated some degree of reactivity to multiple ebolavirus species and, in some instances, Marburg virus. All 5 of these survivors had immunoreactivity to EBOV glycoprotein (GP) and EBOV VP40, and 4 had reactivity to EBOV nucleoprotein (NP). Three of these survivors showed sero-logic responses to the 3 species of ebolavirus GPs tested (EBOV, BDBV, SUDV). All 5 samples also exhibited ability to neutralize EBOV using live virus, in a plaque reduction neutralization test. Remarkably, 3 of these EBOV survivors had plasma antibody responses to MARV GP. In pseudovirus neutralization assays, serum antibodies from a subset of these survivors also neutralized EBOV, BDBV, SUDV, and Taï Forest virus as well as MARV. Collectively, these findings suggest that some survivors of naturally acquired ebolavirus infection mount not only a pan-ebolavirus response, but also in less frequent cases, a pan-filovirus neutralizing response.
AB - One year after a Zaire ebolavirus (EBOV) outbreak occurred in the Boende Health Zone of the Democratic Republic of the Congo during 2014, we sought to determine the breadth of immune response against diverse filoviruses including EBOV, Bundibugyo (BDBV), Sudan (SUDV), and Marburg (MARV) viruses. After assessing the 15 survivors, 5 individuals demonstrated some degree of reactivity to multiple ebolavirus species and, in some instances, Marburg virus. All 5 of these survivors had immunoreactivity to EBOV glycoprotein (GP) and EBOV VP40, and 4 had reactivity to EBOV nucleoprotein (NP). Three of these survivors showed sero-logic responses to the 3 species of ebolavirus GPs tested (EBOV, BDBV, SUDV). All 5 samples also exhibited ability to neutralize EBOV using live virus, in a plaque reduction neutralization test. Remarkably, 3 of these EBOV survivors had plasma antibody responses to MARV GP. In pseudovirus neutralization assays, serum antibodies from a subset of these survivors also neutralized EBOV, BDBV, SUDV, and Taï Forest virus as well as MARV. Collectively, these findings suggest that some survivors of naturally acquired ebolavirus infection mount not only a pan-ebolavirus response, but also in less frequent cases, a pan-filovirus neutralizing response.
KW - DRC
KW - Ebola
KW - Filovirus
KW - Immune response
UR - http://www.scopus.com/inward/record.url?scp=85056270218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056270218&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiy453
DO - 10.1093/infdis/jiy453
M3 - Article
C2 - 30107445
AN - SCOPUS:85056270218
SN - 0022-1899
VL - 218
SP - 1929
EP - 1936
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 12
ER -